Skip to main content
    S

    Serina Therapeutics Inc (SER)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $1.36
    -0.05 (-3.87%)

    Market Cap: $37.73M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Serina Therapeutics Inc (SER) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Serina Therapeutics (SER) has a market cap of $37.73M and an enterprise value of $21.50M. It kept -19596.80% of revenue as net income over the last 12 months. Its share count is up 145.80% from a year earlier.

    Total Valuation

    Enterprise value is 43.02% below the market cap, as cash exceeds debt.

    Market Cap$37.73M
    Enterprise Value$21.50M
    Latest price (Nov 17, 2026)$1.36

    Key Dates

    The next earnings report is expected on May 10, 2027, covering the quarter ending Mar 31, 2027.

    Next Earnings DateMay 10, 2027 (expected)
    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 55.10% in the quarter ended Sep 30, 2026 and grew 69.45% a year over 2 years.

    Shares Outstanding25.41M
    Shares Change (YoY)+145.80%
    Shares Change (QoQ)+55.10%
    Share Count Growth (2Y CAGR)+69.45%

    Valuation Ratios

    Sales and book value multiples are 277.5x and 2.5x. Its year-end P/S ranged from 147.2x to 621.5x from 2019 to 2025.

    P/S Ratio277.5x
    P/B Ratio2.5x

    Valuation history and multiples

    Price Statistics

    The stock is down 66.63% over 52 weeks and trades 28.04% below its 50-day average.

    Beta (1Y)1.27
    52-Week Change-66.63%
    1-Month Change-17.27%
    3-Month Change-49.82%
    6-Month Change-15.22%
    5-Year Change-93.29%
    Total Return (1Y)-66.63%
    Total Return (3Y CAGR)-55.37%
    Total Return (5Y CAGR)-45.13%
    Return vs SPY (1Y)-75.26%
    Max Drawdown (1Y)-69.95%
    Max Drawdown (3Y)-94.27%
    Sharpe Ratio (1Y)-0.83
    Correlation with SPY (1Y)0.14
    50-Day Average$1.89
    200-Day Average$2.01
    52-Week Range$1.14 to $4.26
    RSI (14 Days)34.0
    Average Volume (20 Days)73.01K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 4.62x current liabilities, and total debt is 0.23x shareholder equity.

    Current Ratio4.62x
    Quick Ratio4.62x
    Debt / Equity0.23x
    Interest Coverage10.44x

    Returns and Efficiency

    Return on invested capital is -109.44% and return on equity is -175.99% over the last 12 months.

    Return on Equity (ROE)-175.99%
    Return on Assets (ROA)-111.99%
    Return on Invested Capital (ROIC)-109.44%
    Return on Capital Employed (ROCE)-136.51%
    Asset Turnover0.01x

    Scores

    SER has an Altman Z-Score of -5.47, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score-5.47
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $125.00K over the last 12 months is up 7.76% from the 12 months before.

    Revenue$125.00K
    Revenue Growth (YoY)+7.76%
    Gross Profit$102.00K
    Operating Income-$27.13M
    Pretax Income-$24.47M
    Net Income-$24.50M
    EBITDA-$23.31M
    EBIT-$23.68M
    Reported EPS (TTM)-$1.70

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 63.65% of the $21.87M in total assets.

    Cash and Equivalents$19.40M
    Total Debt$3.17M
    Net Cash$16.23M
    Net Cash Per Share$0.64
    Working Capital$16.40M
    Shareholder Equity$13.92M
    Book Value Per Share$0.55
    Total Assets$21.87M
    Total Liabilities$7.95M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $115.00K of capital spending, operating cash flow left -$22.89M of free cash flow.

    Operating Cash Flow-$22.78M
    Capital Expenditures$115.00K
    Free Cash Flow-$22.89M
    FCF Per Share-$0.90
    Depreciation and Amortization$364.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -21705.60%.

    Gross Margin81.60%
    Operating Margin-21705.60%
    Pretax Margin-19576.80%
    Net Margin-19596.80%
    EBITDA Margin-18650.40%
    EBIT Margin-18941.60%
    FCF Margin-18316.00%
    Gross Margin (5Y Average)89.71%

    Growth

    Revenue grew 56.37% a year over 3 years.

    Revenue Growth (3Y CAGR)+56.37%
    Revenue Growth (5Y CAGR)-18.48%

    Revenue and profit by year

    Dividends and Yields

    SER does not pay a dividend. Its free cash flow yield is -65.83%.

    FCF Yield-65.83%
    Buyback Yield-96.88%
    Shareholder Yield-96.88%

    Stock Splits

    The last split was a 1-for-36 reverse split on Mar 15, 2024.

    Last Split DateMar 15, 2024
    Split TypeReverse split
    Split Ratio1:36

    Peer Position

    Against 5 similar companies, SER has the highest P/S.

    P/S Ratio277.5x vs 6.6x median
    ROIC-109.44% vs -91.22% median
    Revenue Growth (Trailing 4 Quarters, YoY)+7.76% vs -49.61% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About SER

    What is SER's market cap?

    Serina Therapeutics has a market cap of $37.73M. Its enterprise value, which adds debt and subtracts cash, is $21.50M.

    How many shares of SER are outstanding?

    Serina Therapeutics has 25.41M shares outstanding. The count is up 145.80% from a year earlier.

    Does SER pay a dividend?

    No. Serina Therapeutics does not pay a dividend.

    How much debt does SER have?

    Serina Therapeutics has $3.17M of total debt and $19.40M of cash and equivalents, a net cash position of $16.23M.